Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022
/PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, today shares...
Source: prnewswire.com